Reposted by Radek Nowak
Congrats to Frontier Medicines on their covalent p53 Y220C activator FMC-220! www.globenewswire.com/news-release...
globenewswire.com
Frontier Medicines Announces FMC-220, the First Covalent p53 Y220C Activator Development Candidate, with Best-in-Class Potential
FMC-220 is a first-in-class covalent activator of p53Y220C designed to address potency and tolerability challenges of non-covalent approachesIn preclinical...